Scientific article

Parameters for successful monthly extended dosing of darbepoetin-alpha in patients undergoing hemodialysis

Published inClinical nephrology, vol. 71, no. 6, p. 697-702
Publication date2009

AIM: To document the feasibility and report the results of dosing darbepoetin-alpha at extended intervals up to once monthly (QM) in a large dialysis patient population. MATERIAL: 175 adult patients treated, at 23 Swiss hemodialysis centres, with stable doses of any erythropoiesis-stimulating agent who were switched by their physicians to darbepoetin-alpha treatment at prolonged dosing intervals (every 2 weeks [Q2W] or QM). METHOD: Multicentre, prospective, observational study. Patients' hemoglobin (Hb) levels and other data were recorded 1 month before conversion (baseline) to an extended darbepoetin-alpha dosing interval, at the time of conversion, and once monthly thereafter up to the evaluation point (maximum of 12 months or until loss to follow-up). RESULTS: Data for 161 evaluable patients from 23 sites were included in the final analysis. At 1 month prior to conversion, 73% of these patients were receiving darbepoetin-alpha weekly (QW) and 27% of the patients biweekly (Q2W). After a mean follow-up of 9.5 months, 34% received a monthly (QM) dosing regimen, 52% of the patients were receiving darbepoetin-alpha Q2W, and 14% QW. The mean (SD) Hb concentration at baseline was 12.3 +/- 1.2 g/dl, compared to 11.9 +/- 1.2 g/dl at the evaluation point. The corresponding mean weekly darbepoetin-alpha dose was 44.3 +/- 33.4 microg at baseline and 37.7 +/- 30.8 microg at the evaluation point. CONCLUSIONS: Conversion to extended darbepoetin-alpha dosing intervals of up to QM, with maintenance of initial Hb concentrations, was successful for the majority of stable dialysis patients.

  • Aged
  • Algorithms
  • Anemia/blood/etiology/prevention & control
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Monitoring/methods
  • Erythropoietin/administration & dosage/analogs & derivatives
  • Feasibility Studies
  • Female
  • Hematinics/administration & dosage
  • Hemoglobins/analysis
  • Humans
  • Kidney Failure, Chronic/blood/complications/therapy
  • Male
  • Middle Aged
  • Prospective Studies
  • Renal Dialysis/statistics & numerical data
  • Treatment Outcome
Citation (ISO format)
TRACHSLER, J. et al. Parameters for successful monthly extended dosing of darbepoetin-alpha in patients undergoing hemodialysis. In: Clinical nephrology, 2009, vol. 71, n° 6, p. 697–702. doi: 10.5414/cnp71697
ISSN of the journal0301-0430

Technical informations

Creation03/17/2010 4:46:00 PM
First validation03/17/2010 4:46:00 PM
Update time03/14/2023 3:25:16 PM
Status update03/14/2023 3:25:16 PM
Last indexation01/15/2024 7:37:42 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack